OLIPASS Corporation

A244460

KR7244460002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 03/06/2024 am IST			5-day change	1st Jan Change
496 ^KRW	+2.90%		+1.85%	-35.92%

18/03	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	CI
06/03	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	CI

OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors

November 30, 2020

On November 30, 2020, OLIPASS Corporation (KOSDAQ:A244460) closed the transaction.

Latest news about OLIPASS Corporation

OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	18/03	CI
OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	06/03	CI
OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding	18/12	CI
OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002	13/11	CI
OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding	18/23/18	CI
OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding	04/23/04	CI
OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding	04/23/04	CI
OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index	24/23/24	CI
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients	16/23/16	CI
OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.	13/22/13	CI
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics	30/22/30	CI
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002	18/22/18	CI
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002	18/22/18	CI
OLIPASS Corporation Announces SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage	25/21/25	CI
OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors	30/20/30	CI
OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors	18/20/18	CI
OLIPASS Corporation(KOSDAQ:A244460) added to S&P Global BMI Index	21/20/21	CI
OLIPASS Corporation announced that it has received KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	20/19/20	CI
OLIPASS Corporation announced that it expects to receive KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.	18/19/18	CI
OLIPASS Corporation has completed an IPO in the amount of KRW 14 billion.	19/19/19	CI
OLIPASS Corporation has filed an IPO.	22/19/22	CI
Olipass Co., Ltd. announced that it has received KRW 19.99992 billion in funding from a group of investors	30/17/30	CI
Olipass Co., Ltd. announced that it expects to receive KRW 19.99992 billion in funding from SV Investment Corp., Geon Investment Co., Ltd., Mirae Asset Venture Investment Co., Ltd., KDB Capital Corporation, Investment Arm, Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm	06/17/06	CI
OLIPASS Corporation announced that it has received KRW 2.00002 billion in funding	10/17/10	CI

OliPass Corporation is a Korea-based company principally engaged in the research and development of bio medicine. The Company principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.

Sector

Biotechnology & Medical Research

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OLIPASS CORPORATION	-35.92%	1.21Cr
VERTEX PHARMACEUTICALS INCORPORATED	+14.64%	12TCr
REGENERON PHARMACEUTICALS, INC.	+13.26%	11TCr
BIONTECH SE	-3.25%	2.43TCr
ARGENX SE	+1.14%	2.2TCr
GENMAB A/S	-9.35%	1.82TCr
WUXI APPTEC CO., LTD.	-42.28%	1.64TCr
BEIGENE, LTD.	-18.38%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+5.88%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+28.70%	1.23TCr

Bio Therapeutic Drugs